TrialESMO open2020

Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy.

Edward B Garon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.